Scientists identify four core biological drivers that fuel multiple age-related diseases simultaneously: genomic instability, epigenetic dysregulation, mitochondrial dysfunction, and stem cell exhaustion. Rather than treating each chronic condition separately, targeting these shared pathways could prevent cardiovascular disease, diabetes, cancer, and neurodegeneration together. This represents a fundamental shift in medical thinking—from reactive disease treatment to proactive aging intervention. The approach leverages senolytic drugs that eliminate damaged cells and epigenetic reprogramming techniques that reset cellular age markers. However, significant translation barriers remain formidable. Animal studies showing remarkable life extension often fail to replicate in humans, highlighting species-specific differences in aging biology. Safety concerns around cellular reprogramming persist, as improperly controlled rejuvenation could trigger cancer-like cellular behavior. Sex-based differences in therapeutic responses suggest one-size-fits-all approaches may prove inadequate. The integration of AI-driven drug discovery and organ-on-chip models offers promise for more precise interventions, but the field remains largely experimental. While conceptually revolutionary, geroscience faces the challenge of proving that targeting aging mechanisms can deliver the promised compression of morbidity in diverse human populations.